



CLIENT CODE : CA00008666
CLIENT'S NAME AND ADDRESS :
COSMOPOLITAN HOSPITAL
MURINJAPALAM
THIRUVANANTHAPURAM
TRIVANDRUM 695011
KERALA INDIA
0471 2521453

DDRC SRL DIAGNOSTICS
GH TRIVANDRUM
KERALA, INDIA
Tel : 93334 93334
Email : customercare.ddrc@srl.in

PATIENT NAME : JAYARAMPATIENT ID : **JAYAM0912604182**ACCESSION NO : **4182VL003938** AGE : 62 Years SEX : Male

DRAWN : 09-12-2022 18:11

RECEIVED : 09-12-2022 18:19

REPORTED : 10-12-2022 02:26

REFERRING DOCTOR : DR. SHAFEEQUE M, DM NEURO

CLIENT PATIENT ID : 01399608

CLINICAL INFORMATION :SRF ID : 1006/TVM/2022121414
ICMR Registration No: DDRC SRLDPTK

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MOLECULAR BIOLOGY**COVID 19 RT PCR**

SPECIMEN	Nasopharyngeal / oropharyngeal Swab
N GENE	NOT DETECTED
ORF1ab/RDRP	NOT DETECTED
RESULT	SARS CoV-2 RNA NOT DETECTED
FINAL REPORT	NEGATIVE

Interpretation(s)

COVID 19 RT PCR-Method: Real-time PCR, This is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the 2019-nCoV in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) collected from individuals who meet 2019-nCoV clinical and/or epidemiological criteria. The assay uses RNA extracted from clinical samples. Using the RNA extracted, the assay performs the RT-PCR reaction by dividing it into two assays for accurate detection of SARS-CoV-2. Each assay amplifies E gene and the COVID -19 specific target, RdRp gene, if present; thus it is designed for both the screening and specific detection of 2019-nCoV.

Pathogen information: Coronaviruses are non-segmented positive-stranded RNA viruses with a roughly 30 kb genome surrounded by a protein envelope. Most coronaviruses cause diseases in their particular host species; those that can infect humans through cross-species transmission have become an important threat to public health. Since December, 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recognised as the causal factor in a series of severe cases of pneumonia originating in Wuhan in Hubei province, China. This disease has been named coronavirus disease 2019 (COVID-19) by WHO. Severe acute respiratory syndrome-related coronavirus (SARSr-CoV) is a species of coronavirus that infects humans, bats and certain other mammals. It is a member of the genus Betacoronavirus and subgenus sarbecoronavirus. Two strains of the virus have caused outbreaks of severe respiratory diseases in humans: SARS-CoV, which caused the 2002-2004 outbreak of severe acute respiratory syndrome (SARS), and SARS-CoV-2, which is causing the 2019-20 pandemic of coronavirus disease 2019 (COVID-19). Other strains of Sarbecovirus are only known to infect non-human species: bats are a major reservoir of many strains.

Interpretation: Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. A false negative result may occur, if inadequate number of organisms are present in the specimen due to improper collection, transport or handling. False negative results may also occur if amplification inhibitors are present in the specimen. A single negative test result, particularly if this is from an upper respiratory tract specimen, does not exclude infection. Repeat sampling and testing of lower respiratory specimen is strongly recommended in severe or progressive disease. The repeat specimens may be considered after a gap of 2 - 4 days after the collection of the first specimen for additional testing if required.

For inconclusive results, repeat testing is recommended on a fresh specimen after three days for further confirmation

DDRC SRL cannot guarantee the integrity of Covid19 specimens collected or sourced from outside DDRC SRL collection centres. It is the responsibility of those collection points to ensure proper methods of sample collection and transportation.

****End Of Report******Please visit www.srlworld.com for related Test Information for this accession**

Scan to View Details



Scan to View Report



CLIENT CODE : CA00008666
CLIENT'S NAME AND ADDRESS :
COSMOPOLITAN HOSPITAL
MURINJAPALAM
THIRUVANANTHAPURAM
TRIVANDRUM 695011
KERALA INDIA
0471 2521453

DDRC SRL DIAGNOSTICS
GH TRIVANDRUM
KERALA, INDIA
Tel : 93334 93334
Email : customercare.ddrc@srl.in

PATIENT NAME : JAYARAM

PATIENT ID : **JAYAM0912604182**

ACCESSION NO : **4182VL003938** AGE : 62 Years SEX : Male

DRAWN : 09-12-2022 18:11

RECEIVED : 09-12-2022 18:19

REPORTED : 10-12-2022 02:26

REFERRING DOCTOR : DR. SHAFEEQUE M, DM NEURO

CLIENT PATIENT ID : 01399608

CLINICAL INFORMATION :

SRF ID : 1006/TVM/2022121414
ICMR Registration No: DDRC SRLDPTK

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

VISHNU AJITH , MSc
LAB SUPERVISOR
MOLECULAR BIOLOGY &
GENETICS

DR.RATHEESHKUMAR T, Ph.D
HOD-MOLECULAR BIOLOGY &
GENETICS



Scan to View Details



Scan to View Report